KKR closed an all-cash transaction valued at $5.7 billion to take Integer Holdings private, removing a $4.2 billion market-cap medical-device manufacturer from public equity markets. The deal—announced via Reuters on August 3, 2026—marks KKR's largest single healthcare take-private since its $3.9 billion Envision Healthcare acquisition in 2018. Integer supplies cardiac rhythm management devices, neuromodulation systems, and surgical tools to Medtronic, Abbott, and Boston Scientific.

Integer generated $1.47 billion in trailing twelve-month revenue as of Q2 2026, with 83% derived from recurring Original Equipment Manufacturer contracts. The company operates 22 manufacturing facilities across the U.S., Mexico, and Switzerland, employing 7,800 workers. KKR's offer represents a 34% premium to Integer's 30-day volume-weighted average price prior to deal rumors surfacing in mid-July. Integer's management cited PE's longer capital horizon as enabling multi-year R&D commitments that public-market quarterly scrutiny prevented. The transaction is expected to close in Q4 2026, subject to customary regulatory clearances and shareholder approval.

This marks KKR's third healthcare infrastructure bet exceeding $5 billion in eighteen months, following its $6.4 billion Cotiviti take-private in March 2025 and $5.1 billion stake in Lifescience Dynamics in November 2025. The firm is repositioning capital toward businesses that sell directly into hospital and clinic supply chains rather than consumer-facing diagnostics. Integer's customer concentration—Medtronic alone accounts for 29% of revenue—creates predictable cash flows but also dependency risk. KKR's healthcare vertical now controls $47 billion in assets under management, the majority in B2B infrastructure rather than patient-facing services. The deal also removes a volatile equity story: Integer's share price ranged from $68 to $142 over the past twelve months, driven by device reimbursement uncertainty and FDA approval timelines. Private ownership allows Integer to absorb margin compression from Medicare rate cuts without quarterly earnings calls.

Allocators should monitor three follow-on events. First, whether KKR recapitalizes Integer's $1.1 billion term loan B within six months of close, typically a signal of operational overhaul or bolt-on M&A. Second, Integer's contract renewal negotiations with Abbott and Boston Scientific, both expiring in Q2 2027, will reveal pricing power under new ownership. Third, KKR's ability to exit via strategic sale to a device OEM within four to six years hinges on Integer expanding beyond cardiac and neuro into higher-margin orthopedic and robotic surgery components—a pivot requiring $200 million to $300 million in incremental capex.

KKR's healthcare infrastructure thesis now controls the supply chain for devices implanted in 1.4 million U.S. patients annually.